1. 养正透邪祛毒法联合NAC 方案化疗对三阴性乳腺癌 患者疗效、T 细胞亚群及癌因性疲乏的影响.
- Author
-
谷晓娟, 谢昱伟, 李 萌, 左晓娜, 王 佳, 刘 欣, and 胡志伟
- Abstract
OBJECTIVE: To probe into the effects of Yangzheng Touxie Qudu method combined with NAC regimen (docetaxel + epirubicin + cyclophosphamide) chemotherapy on efficacy, T cell subsets and cancer-related fatigue in patients with triple negative breast cancer. METHODS: From Jun. 2022 to Jun. 2023, totally 100 cases of triple negative breast cancer diagnosed and treated in the hospital were extracted to be divided into the control group and observation group according to the random number table method, with 50 cases in each group. The control group was treated with NAC regimen, while the observation group received self formulated Yangzheng Touxie Qudu formula combined with NAC regimen. The efficacy, T-lymphocyte subsets, inflammatory factors, cancer-related fatigue levels, and incidence of adverse drug reactions of two groups were observed. RESULTS: The total effective rate of observation group was 82. 00% (41/50), significantly higher than that 58. 00% (29/50) of control group, the difference was statistically significant (P < 0. 05). Compared with before treatment, CD3+, CD4+, CD4+ / CD8+, interleukin (IL)-12 and IL-2 levels increased significantly in both groups after treatment, and the observation group was higher than the control group; compared with before treatment, CD8+, tumor necrosis factor-α, soluble interleukin-2 receptor levels, physical, cognitive and emotional fatigue scores decreased in both groups after treatment, and the observation group was lower than the control group, with statistically significant differences (P <0.05). The incidence of adverse drug reactions in observation group and control group was respectively 24.00% (12/50) and 28.00% (14/50), with no statistically significant difference (P>0.05). CONCLUSIONS: Yangzheng Touxie Qudu method combined with NAC regimen in the treatment of patients with triple negative breast cancer can significantly improve the efficacy and T cell subsets levels, reduce inflammatory reactions, and improve cancer-related fatigue with higher safety. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF